A detailed history of Parallel Advisors, LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Parallel Advisors, LLC holds 773 shares of MYGN stock, worth $10,621. This represents 0.0% of its overall portfolio holdings.

Number of Shares
773
Previous 773 -0.0%
Holding current value
$10,621
Previous $18,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$17.98 - $25.47 $53 - $76
-3 Reduced 0.39%
773 $18,000
Q1 2024

May 06, 2024

SELL
$17.59 - $23.59 $580 - $778
-33 Reduced 4.08%
776 $16,000
Q4 2023

Feb 09, 2024

BUY
$13.91 - $21.32 $9,848 - $15,094
708 Added 700.99%
809 $15,000
Q2 2023

May 20, 2024

SELL
$17.56 - $23.76 $175 - $237
-10 Reduced 9.01%
101 $2,000
Q2 2023

Aug 04, 2023

SELL
$17.56 - $23.76 $175 - $237
-10 Reduced 9.01%
101 $2,000
Q1 2023

May 20, 2024

SELL
$15.26 - $23.75 $10,147 - $15,793
-665 Reduced 85.7%
111 $2,000
Q1 2023

Apr 25, 2023

SELL
$15.26 - $23.75 $183 - $285
-12 Reduced 9.76%
111 $2,000
Q4 2022

Feb 03, 2023

BUY
$14.51 - $20.99 $43 - $62
3 Added 2.5%
123 $1,000
Q3 2022

Nov 10, 2022

BUY
$18.21 - $27.88 $345 - $529
19 Added 18.81%
120 $2,000
Q2 2022

Aug 01, 2022

BUY
$16.45 - $25.88 $164 - $258
10 Added 10.99%
101 $2,000
Q3 2021

Nov 02, 2021

BUY
$29.97 - $36.66 $569 - $696
19 Added 26.39%
91 $3,000
Q1 2021

Apr 23, 2021

BUY
$19.92 - $31.6 $1,434 - $2,275
72 New
72 $2,000
Q4 2018

Feb 05, 2019

SELL
$27.23 - $45.56 $381 - $637
-14 Closed
0 $0
Q3 2018

Nov 01, 2018

BUY
$37.57 - $50.34 $525 - $704
14 New
14 $1,000

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.11B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.